DrugPatentWatch Database Preview

qinlock Drug Patent Profile

Email this page to a colleague

« Back to Dashboard

When do Qinlock patents expire, and when can generic versions of Qinlock launch?

Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-eight patent family members in ten countries.

The generic ingredient in QINLOCK is ripretinib. Additional details are available on the ripretinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Qinlock

Qinlock will be eligible for patent challenges on May 15, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 7, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for qinlock

International Patents:	28
US Patents:	4
Applicants:	1
NDAs:	1
Clinical Trials:	1
What excipients (inactive ingredients) are in qinlock?	qinlock excipients list
DailyMed Link:	qinlock at DailyMed

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for qinlock

NDA:

213973

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for qinlock

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Deciphera Pharmaceuticals LLC	Phase 1

See all qinlock clinical trials

ATC Classes for qinlock

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for qinlock

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes			Y	Y
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes			Y	Y
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes

International Patents for qinlock

Country	Patent Number	Estimated Expiration
Australia	2007296441
China	101516379
Eurasian Patent Organization	026730
Brazil	PI0716981
European Patent Office	2063897
Eurasian Patent Organization	016055
Eurasian Patent Organization	200970279